They investigated a functional role of this pathway in a metastatic CRC cell line called CTC-MCC-41 and suggested that therapies targeting AKT and mTOR could be beneficial for targeting CTCs in CRC and possibly other tumor types [61]. The gene discussed is MTOR; the disease is colorectal carcinoma.